Beijing Scitop Bio-tech Co., Ltd. (SHE:300858)
17.92
-0.20 (-1.10%)
At close: Feb 13, 2026
Beijing Scitop Bio-tech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 351.04 | 302.37 | 298.87 | 368.24 | 364.09 | 339.16 |
Other Revenue | 0.43 | 0.43 | 0.37 | 0.93 | 0.52 | - |
| 351.47 | 302.79 | 299.24 | 369.17 | 364.62 | 339.16 | |
Revenue Growth (YoY) | 16.76% | 1.19% | -18.94% | 1.25% | 7.51% | 10.08% |
Cost of Revenue | 154.36 | 126.41 | 135.91 | 177.29 | 181.17 | 175.27 |
Gross Profit | 197.11 | 176.38 | 163.33 | 191.88 | 183.45 | 163.88 |
Selling, General & Admin | 69.01 | 67.9 | 58.03 | 56.86 | 63.26 | 40.5 |
Research & Development | 36.83 | 36.33 | 34.19 | 22.09 | 27.15 | 17.57 |
Other Operating Expenses | 13.22 | 5.27 | 4.92 | 3.76 | 3.06 | 2.88 |
Operating Expenses | 119.41 | 106.35 | 98.94 | 83.43 | 93.81 | 60.5 |
Operating Income | 77.69 | 70.03 | 64.39 | 108.45 | 89.64 | 103.38 |
Interest Expense | -0.16 | -0.25 | -0.5 | -0.41 | -0.44 | - |
Interest & Investment Income | 22.36 | 28.34 | 30.13 | 12.82 | 18.35 | 6.87 |
Other Non Operating Income (Expenses) | 0.59 | -0.03 | -0.05 | -0.05 | -0.04 | -0.04 |
EBT Excluding Unusual Items | 100.49 | 98.08 | 93.97 | 120.81 | 107.52 | 110.21 |
Gain (Loss) on Sale of Investments | 1.96 | 2.01 | 1.26 | 0.17 | 1.55 | - |
Gain (Loss) on Sale of Assets | 0.09 | 0.65 | 0.03 | -0.01 | 11.2 | 0.01 |
Asset Writedown | -0.31 | -0.31 | -0 | -0 | -0.15 | -1.03 |
Other Unusual Items | 15.41 | 8.39 | 6.78 | 4.69 | 4.06 | 3.98 |
Pretax Income | 117.64 | 108.83 | 102.04 | 125.66 | 124.17 | 113.18 |
Income Tax Expense | 18.24 | 14.47 | 8.56 | 15.76 | 14.63 | 16.6 |
Earnings From Continuing Operations | 99.4 | 94.36 | 93.48 | 109.89 | 109.54 | 96.58 |
Net Income | 99.4 | 94.36 | 93.48 | 109.89 | 109.54 | 96.58 |
Net Income to Common | 99.4 | 94.36 | 93.48 | 109.89 | 109.54 | 96.58 |
Net Income Growth | 7.27% | 0.94% | -14.93% | 0.32% | 13.42% | 3.53% |
Shares Outstanding (Basic) | 261 | 262 | 267 | 224 | 222 | 191 |
Shares Outstanding (Diluted) | 261 | 262 | 267 | 224 | 222 | 191 |
Shares Change (YoY) | -1.26% | -1.87% | 19.09% | 1.00% | 16.50% | 14.28% |
EPS (Basic) | 0.38 | 0.36 | 0.35 | 0.49 | 0.49 | 0.51 |
EPS (Diluted) | 0.38 | 0.36 | 0.35 | 0.49 | 0.49 | 0.51 |
EPS Growth | 8.63% | 2.86% | -28.57% | -0.67% | -2.65% | -9.40% |
Free Cash Flow | -200.78 | -69.38 | -71.21 | 64.28 | 42.7 | 45.39 |
Free Cash Flow Per Share | -0.77 | -0.27 | -0.27 | 0.29 | 0.19 | 0.24 |
Dividend Per Share | 0.150 | 0.150 | 0.150 | 0.200 | 0.333 | 0.370 |
Dividend Growth | - | - | -25.00% | -39.99% | -10.02% | - |
Gross Margin | 56.08% | 58.25% | 54.58% | 51.98% | 50.31% | 48.32% |
Operating Margin | 22.11% | 23.13% | 21.52% | 29.38% | 24.59% | 30.48% |
Profit Margin | 28.28% | 31.16% | 31.24% | 29.77% | 30.04% | 28.48% |
Free Cash Flow Margin | -57.13% | -22.91% | -23.80% | 17.41% | 11.71% | 13.38% |
EBITDA | 106.79 | 94.58 | 82.87 | 125.09 | 104.55 | 113.23 |
EBITDA Margin | 30.38% | 31.23% | 27.69% | 33.88% | 28.68% | 33.38% |
D&A For EBITDA | 29.1 | 24.55 | 18.48 | 16.64 | 14.91 | 9.84 |
EBIT | 77.69 | 70.03 | 64.39 | 108.45 | 89.64 | 103.38 |
EBIT Margin | 22.11% | 23.13% | 21.52% | 29.38% | 24.59% | 30.48% |
Effective Tax Rate | 15.51% | 13.30% | 8.39% | 12.55% | 11.79% | 14.67% |
Revenue as Reported | 351.47 | 302.79 | 299.24 | 369.17 | 364.62 | 339.16 |
Advertising Expenses | - | 23.49 | 19.22 | 7.92 | 9.94 | 10.42 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.